Newcardio (Newcardio) Change In Receivables : $0.09 Mil (TTM As of Sep. 2011)

View and export this data going back to 2006. Start your Free Trial

What is Newcardio Change In Receivables?

Newcardio's change in receivables for the quarter that ended in Sep. 2011 was $0.05 Mil. It means Newcardio's Accounts Receivable declined by $0.05 Mil from Jun. 2011 to Sep. 2011 .

Newcardio's change in receivables for the fiscal year that ended in Dec. 2010 was $-0.04 Mil. It means Newcardio's Accounts Receivable increased by $0.04 Mil from Dec. 2009 to Dec. 2010 .

Newcardio's Accounts Receivable for the quarter that ended in Sep. 2011 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Newcardio's Days Sales Outstanding for the three months ended in Sep. 2011 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Newcardio's liquidation value for the three months ended in Sep. 2011 was $-5.76 Mil.

Newcardio Change In Receivables Historical Data

The historical data trend for Newcardio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newcardio Change In Receivables Chart

Newcardio Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Change In Receivables

Get a 7-Day Free Trial

0.04

-0.04

Newcardio Quarterly Data
	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11
Change In Receivables	Get a 7-Day Free Trial															-0.05	0.04	0.01	-0.01	0.05

Newcardio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09 Mil.

Newcardio (OTCPK:NWCI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Newcardio's Days Sales Outstanding for the quarter that ended in Sep. 2011 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.01	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Newcardio's accounts receivable are only considered to be worth 75% of book value:

Newcardio's liquidation value for the quarter that ended in Sep. 2011 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.013	-	5.772	+	0.75 * 0	+	0.5 * 0
=	-5.76

Newcardio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Newcardio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Newcardio (Newcardio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Newcardio Inc (OTCPK:NWCI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

PO Box 658, Neshanic, Somerset, NJ, USA, 08853

Website

Newcardio Inc. focuses on the research, development and commercialization of products and services for the non-invasive diagnosis and monitoring of cardiovascular disease, as well as the cardiac safety assessment of new drugs under development.

Executives

Mark W Kroll

director

PO BOX 23, CRYSTAL BAY MN 55323

Newcardio (Newcardio) Headlines

No Headlines